Crohn’s Disease diagnosed incident cases set to increase in the 7MM to 2026
The burden of diagnosed Crohn’s Disease (CD) is expected to grow between 2016 and 2026 in the seven major markets
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Flexion’s Zilretta poised to shakeup knee osteoarthritis marketplace
The company anticipates a steady stream of novel therapies to enter the OA marketplace over the next 10 years
Affluent market, medical tourism to steer best-in line drug delivery devices in India
Trends indicate that medical tourism will also bolster the demand for sophisticated devices
Novartis seeks European approval for cell therapy Kymriah
The immunotherapy Kymriah is a key element of Novartis’s efforts to bolster its portfolio of oncology drugs
GSK gets boost for early cancer hopes with breakthrough status
The decision by the Food and Drug Administration paves the way for a speedy regulatory review of the BCMA drug for multiple…
Biotech firms race to recruit good bugs in war on cancer
Certain bacteria seem to help in cancer by priming immune cells and smoothing the path for immunotherapy drugs known as PD-1 drugs
Merck’s drug gets US FDA approval
The drug is expected to be available from December, was approved both as a tablet and an injection
Sandoz says new clinical data support two biosimilars
The trials shows the efficacy and safety of biosimilar adalimumab
Novartis posts eye drug data amid play for Eylea’s turf
The Basel-based drugmaker hopes this latest analysis lends RTH258 additional muscle when matched head-to-head with Eylea
J&J’s Stelara shows promise against lupus in study
J&J said the results were strong enough to advance Stelara into larger Phase III testing